Latest Posts

Congratulations, Dr. Suresh Reddy and team!

Congratulations to our Palliative Care Program for receiving an award at the American Academy of Hospice and Palliative Medicine (AAHPM) in Boston, on March 17, 2018. Under Dr. Suresh Reddy’s leadership, Indo-American Cancer Association (IACA) along with Pallium India took it on themselves to support educational initiatives in palliative care in India. They worked on the curriculum, strengthened the evaluation, and raised funds to support scholarships for palliative care champions from all over the country to participate in educational programs in India.

Congratulations, Dr. Suresh Reddy and team!

One of IACA’s many initiatives is to aid cancer patients who are terminally ill. Every year, thousands of cancer patients will die agonizing deaths with no pain relief, symptomatic care, or support. IACA has committed to making pain and palliative care of cancer patients a key focus of its activities in India.

For more information on our Palliative Care Initiatives:

Hippocratic Screening: An Evening with 2018 Nobel Peace Prize Nominee Dr. Rajagopal

We would like to cordially invite you to the

Houston screening of Hippocratic,

a film exploring 2018 Nobel Peace Prize Nominee Dr. M. R. “Raj” Rajagopal’s extraordinary life as the Father of Palliative Care in India, on

Thursday, April 12th at 8:30 PM.

***Featuring a Q&A session after the film with Dr. Raj himself.***



Dr. Raj is one of the nominees for the 2018 Nobel Peace Prize and recipient of the 2018 Padma Shri, the fourth highest civilian award presented by the Government of India, for his pioneering work in palliative care. Dr. Raj is Chairman of Pallium India and the India Co-Chair of our Palliative Care Fellowship Program in collaboration with MD Anderson Cancer Center.

The Palliative Care Fellowship Program is a six weeks residential course in palliative course has been a huge success having trained about 120 candidates in the last 3 years. The scholarship is given free to a selected physicians and nurses in India to undergo the course. The data has been presented in both India and USA in scientific medical meetings. The ultimate goal of this mission is to help underserved patients and families in India who are suffering from cancer pain and facing death.

The film Hippocratic is based on Dr. Raj’s dedicated work on terminal cancer patients in India and the role he played in changing morphine rules and accessibility to deserving patients.

Date: Thursday, April 12th, 2018, 8:30 PM – 10:30 PM

Location: Edwards Greenway Grand Palace Stadium 24 & RPX,

3839 Weslayan St., Houston, TX 77027

Tickets: $12.71 (plus additional booking fee of $1.75 per ticket)



*Unlike a traditional movie showing, the Demand Film screening requires that 44 more tickets be reserved in the next 2 weeks in order for the screening to occur. We’re going to need your help if we’re going to make this event happen. We’d love to see you in the audience and we’d really appreciate you helping us spread the word. Tell your friends and have them join us for this special one-time screening of Hippocratic in Houston!

For information on screenings in other cities, please visit the film website.

IACA Outstanding Achievement Awards in Hematology, 2017

Dear Friends,

I am honored to announce that this year’s recipients of IACA’s Lifetime Achievement Award for Outstanding Contributions to Hematology-Oncology are Dr. Sagar Lonial and Dr. Vikram Mathews.

Dr. Sagar Lonial is the Chair of the Department of Hematology & Medical Oncology at Emory University School of Medicine and Chief Medical Officer at Winship Cancer Institute of Emory University. He is internationally recognized as a leading authority in multiple myeloma treatment and research. He completed his Hematology-Oncology training at Emory University, and prior to that received his internal medicine residency at the Baylor College of Medicine in Houston. There he spent an additional year as a Chief Medical Resident at the Ben Taub General Hospital as well as the Texas Heart Institute and St. Luke’s Hospital. Dr. Lonial has worked in the field of immunotherapy and cancer since his arrival at Emory, and in the previous 3 years has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. Dr. Lonial’s previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen, and he has completed several trials evaluating the impact of cytokines on dendritic cell content and post transplant immune recovery. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway. His lab has recently received funding from the Multiple Myeloma Research Foundation, the Lymphoma Research Foundation, and The Leukemia & Lymphoma Society. Dr. Lonial has authored or coauthored over 200 peer-reviewed publications.

Dr. Vikram Mathews is the Head of the Department of Hematology at Christian Medical College, Vellore. He is internationally recognized as a leading authority in leukemia treatment and research. Following completion of his specialty training in Clinical Hematology under the guidance of Dr. Mammen Chandy, he spent three years in Washington University in St. Louis as a post-doctoral fellow in the laboratory of Dr. Timothy Graubert and Dr. John DiPersio. During this period, Dr. Mathews was trained in stem cell and leukemia biology and was involved in establishing mouse models of some of these conditions and in evaluating stem cell plasticity. He has since worked and published on various aspects of diagnosis, prognostication, and treatment of acute leukemia in India. An innovative therapeutic strategy and novel protocol of using arsenic trioxide as frontline therapy in acute promyelocytic leukemia (APL) was reported by Dr. Mathews’ team. Dr. Mathews has conducted both single and multi-center clinical trials with this agent in India. The cost effective therapy has been widely cited and was instrumental in moving this drug to frontline therapy worldwide in the treatment of APL. He is currently involved in evaluation of mechanisms of resistance in leukemia with a focus on the role of microenvironment on drug resistance leukemia. Dr. Mathews has published their work on the mechanism of resistance to arsenic mediated by the environment and strategies that can overcome it in Leukemia 30(11), 2169-2178. Dr. Mathews and his team have translated this work into an ongoing clinical trial and reported on promising data from that study in Blood 128(22), 446-446.

Past recipients of IACA’s Lifetime Achievement Award for Outstanding Contributions to Hematology-Oncology include Dr. Nikhil Munshi, Dr. Ranjana Advani, Dr. Vincent Rajkumar, Dr. Mohandas Narla, and Dr. Sundar Jaggannath. We hope you will join us this year to honor Dr. Sagr Lonial and Dr. Vikram Mathews and take part in hearing their incredible stories.

Dr. Swaminathan P. Iyer
Houston Methodist Hospital
President, IACA

IACA Rising Star Award in Hematology, 2017

Dear Friends,

I am honored to announce that this year’s recipient of IACA’s Rising Star Award in Hematology is Dr. Naval Daver.

Dr. Naval Daver completed his fellowship and joined the UT M.D. Anderson Cancer Center’s Leukemia Department in 2011 as an Assistant Professor. His primary areas of interest are AML and MPNs. He is currently PI on 12 ongoing clinical trials (7 of these are investigator initiated studies) and Co-PI on >15 trials in the Department of Leukemia. These trials focus on developing a personalized therapy approach by targeting specific mutations or antigens expressed by patients with AML and myelofibrosis, identifying novel combinations of these targeted and novel cytotoxic agents, and overcoming mechanism of resistance. On a translational level, Dr. Daver’s research focuses on the resistance mechanisms that are at work in various therapies with the objective that they can tailor therapy for the individual patient and develop combination therapies to improve efficacy of single agents. Dr. Daver has published 97 peer-reviewed manuscripts, including 30 first author publications in the last 4.5 years mainly focusing on molecular and combination therapy strategies in AML and MPNs. The role of immune therapies including checkpoint therapies, vaccines, CAR-T cell therapies in AML remain poorly defined. Dr. Daver and his colleagues have developed one of the largest immunotherapy for hematologic malignancies programs in the country with 12 checkpoint inhibitor trials, DC vaccine trials, and is leading this program with Dr. Kantarjian in the Department of Leukemia at MDACC.

Past recipients of IACA’s Rising Star Award in Hematology include Dr. Mrinal Patnaik and Dr. Nitin Jain. We hope you will join us this year to honor Dr. Naval Daver and take part in hearing his incredible story.

Dr. Swaminathan P. Iyer
Houston Methodist Hospital
President, IACA

IACA Annual Dinner Meeting at ASCO 2017

Come join us at our Annual Dinner Meeting at ASCO 2017 to honor two deserving oncologist and take part in hearing their incredible stories.

When: Saturday, June 3 at 6:15pm
Where: The Westin Michigan Avenue – Chicago Ballroom
909 North Michigan Avenue, Chicago, IL 60611


While you are at ASCO 2017, also come visit us at our Booth #5035 in the Exhibit Hall.

Traveling Fellowship Online Application Portal

Applications for IACA Traveling Fellowship are being accepted through the Traveling Fellowship online portal


IACA’s Traveling Fellowship is dedicated to improving cancer care in the Indian subcontinent by training cancer specialists from the subcontinent at renowned institutions in the United States.

The Fellowship is open to practicing cancer specialists who are interested in mastering specific skills to improve their work at major government or nonprofit hospitals in the Indian subcontinent. Candidates are selected based on their individual qualifications, recommendation letters from their home institution, and commitment to gaining valuable training for the purpose of practical utilization. Preference is given to candidates whose institutions champion low cost or free medical services to underserved populations and also provide teaching and training to postgraduate doctors.


Please visit for more information and to register.

If you have additional questions, please email

Traveling Fellowship Flyer_1

IACA Annual Meeting at ASCO 2017 – IACA Award for Outstanding Contributions to Oncology & Keynote Speaker

IACA is honored to announce this year’s recipient of IACA Award for Outstanding Contributions to Oncology is Dr. Ravi Salgia. Dr. Salgia is also the keynote speaker at the IACA annual meeting at ASCO 2017.
When:     Saturday, June 3rd 2017 at 6:30 PM
Where:   Westin Michigan Avenue
909 North Michigan Avenue
Chicago, IL 60611
An esteemed physician and translational researcher, Ravi Salgia M.D., Ph.D., is the Arthur & Rosalie Kaplan Chair in Medical Oncology and Therapeutics Research at City of Hope, and the associate director for clinical sciences in City of Hope’s Comprehensive Cancer Center.
Dr. Salgia has over 25 years of experience in translational research and the development of targeted therapies to improve the quality of life and survival of cancer patients, especially as related to small cell lung cancer.  Dr.Salgia was the first to clone the focal adhesion protein paxillin and also localize the gene to 12q24. His laboratory also identified the gain-of-function mutations of paxillin in lung cancer. He went on to define receptor tyrosine kinases and have identified unique targets in lung cancer such as MET/RON and EPHB4 receptor tyrosine kinases. In fact his laboratory elucidated the exon 14 skipping of MET in small cell lung cancer and non-small cell lung cancer that has treatment implications in EGFR mutation lung cancer. His group have also developed a large bioinformatics database for thoracic oncology. He has authored over 330 peer-reviewed articles, reviews and editorials, one book, and 34 book chapters, and has been awarded several NIH grants for his research, as well as several invention discoveries and patents related to his work. He is the current Chief Editor for Cancer Commons, and Associate Editor for a number of journals.  He is internationally known for his scientific accomplishments, and serves as a chartered member of NIH/NCI’s Clinical Oncology Study Section, was elected as the Translational Science Representative on the Thoracic Malignancy Steering Committee of the NCI, and previously served on the NIH Tumor Progression and Metastasis Study Section. At the City of Hope he has developed a large informatics database in thoracic malignancies that is available on the iBridge network.
Prior to joining City of Hope, Dr. Salgia served as tenured professor of medicine, pathology and dermatology; director of the Thoracic Oncology Program and the Aerodigestive Tract Program Translational Research Lab in the section of hematology/oncology; and vice chair for translational research in the department of medicine at the University of Chicago. He was also associate director for translational science at the University of Chicago Comprehensive Cancer Center in Chicago.
Past recipients of this Outstanding Award in Oncology have included Dr. Manjit Singh Bains, Dr. Jatin Shah, Dr. Mansukh Wani, and Dr. Rengaswamy Sankaranarayanan.  We hope you join us this year to honor another deserving oncologist and take part in hearing his incredible story.

 Click here to RSVP

While you are at ASCO 2017, also come visit us at our Booth #5035 in the Exhibit Hall